IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1036 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (303 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References
   Article Tables

 Article Access Statistics
    Viewed1372    
    Printed46    
    Emailed0    
    PDF Downloaded172    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2011  |  Volume : 43  |  Issue : 3  |  Page : 361-362
 

Polypill--Friend or Foe?


Pharmacology and Toxicology Section, Central Drugs Laboratory, Government of India, Ministry of Health and Family Welfare, 3, Kyd Street, Kolkata - 16, India

Date of Web Publication24-May-2011

Correspondence Address:
Rakesh Kumar Rishi
Pharmacology and Toxicology Section, Central Drugs Laboratory, Government of India, Ministry of Health and Family Welfare, 3, Kyd Street, Kolkata - 16
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.81491

Rights and Permissions



How to cite this article:
Rishi RK. Polypill--Friend or Foe?. Indian J Pharmacol 2011;43:361-2

How to cite this URL:
Rishi RK. Polypill--Friend or Foe?. Indian J Pharmacol [serial online] 2011 [cited 2019 Sep 20];43:361-2. Available from: http://www.ijp-online.com/text.asp?2011/43/3/361/81491


Sir,

Cardiovascular disease (CVD) is the most common cause of death in developed countries and will continue to be so in coming years. [1] There is a close association between CVD, stroke, ischemic heart disease, renal failure, and a number of other modifiable risk factors. [1] Since cardiovascular mortality rates are rising in both industrialized nations as well as developing economies like India, there is an urgent need to develop new strategies to overcome this global burden. Newly diagnosed hypertensive patients are now usually prescribed more than one drug. Polypill is a fixed-dose combination of three or more cardiovascular drugs. The idea of polypill was coined by Wald and Law, and as expected, it triggered the debate among the scientists, researchers, and healthcare professionals. [2] It was proposed that a combination of drugs acting by distrait mechanisms would have a synergistic effect in order to increase the life expectancy. [2] Since combination of drugs from different classes cancel out each others' untoward effects, their use as first-line therapy for the treatment of newly diagnosed hypertensive patients is gaining popularity. [3] Wald and Law [2] concluded that a combined pharmacological intervention should reduce ischemic heart disease events by 88% and strokes by 80% in persons at risk. After demonstrating the short-term safety and efficacy in reducing the risk levels, several multidrug formulations have been approved in India for the treatment of cardiovascular disorders [Table 1]. Fixed-dose combination therapy can offer potential advantages over individual drugs, including increased efficacy, reduced incidence of adverse effects, lower healthcare costs, and improved patient compliance through the use of a single dosage form administered once daily. [1] However, there are issues and challenges ahead for the polypill before it gets firmly established in a clinical setting. Some of them include long-term safety and tolerability, long-term efficacy in reducing risk factor levels and cardiovascular events, physician, patient, and societal acceptability, adherence, regulatory requirements, cost, and impact on lifestyle habits. [4] Although more and more combinations are coming out in the market after proving their effectiveness in randomized controlled trials and in large multicenter studies, it is obvious that availability of these polypills would not only create confusion among the practicing cardiologists, but it may also lead to medication errors. This is because of the fact that it is not possible to remember the compositions of all these polypills. It is also difficult to tailor the therapeutic regimen for an individual in terms of number of drugs and their doses. In case of polypill, one is supposed to take a single pill which is supposedly designed to "fit in all sizes." The less number of drugs in a single pill (a statin, nicotinic acid, and aspirin) has been suggested (mini-polypill) for the treatment of combined hyperlipidemia. [5] So, many polypills and so called mini-polypills may create "clinical chaos" in the coming years if they are not dealt with properly. The polypill concept is more spoken and less researched by the medical community. Only time will tell if the polypill is a friend or foe. Till then, it is suggested that a focused postmarketing surveillance is required for the polypill formulations presently marketed in the country. These studies may be well beyond the regulatory requirements so as to establish the safety and efficacy of polypills in the long run.
Table 1: Polypill formulations approved by Central Drugs Standard Control Orgenigetion (CDSCO)

Click here to view


 
  References Top

1.García-Donaire JA, Ruilope LM. Multiple action fixed combination. Present or future? Fundam Clin Pharmacol 2010;24:37-42.  Back to cited text no. 1
    
2.Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.  Back to cited text no. 2
    
3.Rosenthal T, Gavras I. Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis 2006;48:416-25.  Back to cited text no. 3
    
4.Lonn E, Yusuf S. Polypill: The evidence and the promise. Curr Opin Lipidol 2009;20:453-9.  Back to cited text no. 4
    
5.Athyros VG, Tziomalos K, Mikhailidis DP, Pagourelias ED, Kakafika AI, Skaperdas A, et al. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother 2007;8:2267-77.  Back to cited text no. 5
    



 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow